Matching articles for "Pseudomonas aeruginosa"
Issue 1758 · July 6, 2026
Fosfomycin (Contepo) for Complicated Urinary Tract Infections

The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin ( Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible…

Med Lett Drugs Ther. 2026 Jul 6; 68(1758):107-8 doi:10.58347/tml.2026.1758b
The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin ( Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae . Oral fosfomycin has been available in the US for years for treatment of uncomplicated urinary tract infections. IV fosfomycin has been available in other countries for decades.
Issue 1737 · September 15, 2025
Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic

Ceftobiprole medocaril sodium ( Zevtera – Innoviva Specialty Therapeutics), a new IV cephalosporin antibacterial drug, has been approved by the FDA for treatment of Staphylococcus aureus bacteremia (SAB),…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):149-52 doi:10.58347/tml.2025.1737d
Ceftobiprole medocaril sodium ( Zevtera – Innoviva Specialty Therapeutics), a new IV cephalosporin antibacterial drug, has been approved by the FDA for treatment of Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSIs), and community-acquired bacterial pneumonia (CABP) (see Table 1). It is the second cephalosporin with activity against methicillin-resistant S. aureus (MRSA) to be approved in the US; ceftaroline (Teflaro) , which was approved for treatment of ABSSSIs and CABP in 2010, was the first.
Issue 1707 · July 22, 2024
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):117-8 doi:10.58347/tml.2024.1707d
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms (see Spectrum of Activity). Exblifep is the first product that contains enmetazobactam to be approved in the US.
Issue 1616 · January 25, 2021 Free
Antibacterial Drugs for Community-Acquired Pneumonia

Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):10-5
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Issue 1581 · September 23, 2019
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia

Lefamulin ( Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first…

Med Lett Drugs Ther. 2019 Sep 23; 61(1581):145-8
Lefamulin ( Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin (Altabax) , a 1% topical ointment for treatment of impetigo, was approved in 2007.
Issue 1570 · April 22, 2019
Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections

Eravacycline ( Xerava – Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is…

Med Lett Drugs Ther. 2019 Apr 22; 61(1570):61-3
Eravacycline ( Xerava – Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is structurally similar to tigecycline ( Tygacil , and generics), a broad-spectrum tetracycline approved by the FDA for IV treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired pneumonia. A higher rate of mortality has been reported with use of tigecycline compared to other antibacterial drugs; it should be used only when no suitable alternative is available.
Issue 1553 · August 13, 2018
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa

The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by…

Med Lett Drugs Ther. 2018 Aug 13; 60(1553):135-6
The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by Pseudomonas aeruginosa or Staphylococcus aureus in patients ≥6 months old. Otiprio was approved earlier for prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement.
Issue 1543 · March 26, 2018
Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic

The FDA has approved delafloxacin ( Baxdela – Melinta), an anionic fluoroquinolone antibiotic, for oral and parenteral treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs),…

Med Lett Drugs Ther. 2018 Mar 26; 60(1543):49-51
The FDA has approved delafloxacin ( Baxdela – Melinta), an anionic fluoroquinolone antibiotic, for oral and parenteral treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is the first fluoroquinolone to be approved for treatment of MRSA.
Issue 1543 · March 26, 2018
Comparison Table: Some Systemic Fluoroquinolones (online only)

View the Comparison Table: Some Systemic Fluoroquinolones (online only)

Med Lett Drugs Ther. 2018 Mar 26; 60(1543):e57-8
View the Comparison Table: Some Systemic Fluoroquinolones (online only)
Issue 1496 · June 6, 2016
Alternatives to Fluoroquinolones

The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):75-6
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Issue 1469 · May 25, 2015
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic

The FDA has approved ceftazidime/avibactam ( Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options.…

Med Lett Drugs Ther. 2015 May 25; 57(1469):79-80
The FDA has approved ceftazidime/avibactam ( Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options. Ceftolozane/tazobactam ( Zerbaxa – Cubist), another cephalosporin/beta-lactamase inhibitor combination, was approved in 2014.
Issue 1445 · June 23, 2014
Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis

The FDA has approved another solution of the aminoglycoside antibiotic tobramycin ( Bethkis – Chiesi/Cornerstone) for oral inhalation via a nebulizer for management of cystic fibrosis (CF) patients with…

Med Lett Drugs Ther. 2014 Jun 23; 56(1445):51-2
The FDA has approved another solution of the aminoglycoside antibiotic tobramycin ( Bethkis – Chiesi/Cornerstone) for oral inhalation via a nebulizer for management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa .
Issue 131 · July 1, 2013
Drugs for Bacterial Infections

The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of…

Treat Guidel Med Lett. 2013 Jul; 11(131):65-74
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Issue 1419 · June 24, 2013
Tobramycin Inhalation Powder (Tobi Podhaler) for Cystic Fibrosis

Inhaled antibiotics, which can achieve high concentrations in the lung with minimal systemic side effects, are probably the most effective therapy available for chronic Pseudomonas aeruginosa infection in…

Med Lett Drugs Ther. 2013 Jun 24; 55(1419):51-2
Inhaled antibiotics, which can achieve high concentrations in the lung with minimal systemic side effects, are probably the most effective therapy available for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. An orally inhaled dry powder formulation of the aminoglycoside antibiotic tobramycin ( Tobi Podhaler – Novartis) has been approved by the FDA for management of P. aeruginosa pulmonary infection in cystic fibrosis patients ≥6 years old. The new formulation is administered via a hand-held pocket-sized inhaler. Tobramycin is also available as an inhalation solution (Tobi) for administration via a nebulizer. An inhalation solution of aztreonam (Cayston) , administered via a nebulizer, is also approved for this indication.
Issue 1368 · July 11, 2011
Levofloxacin Revisited

A Medical Letter reader has asked us to review the safety of the fluoroquinolone antibiotic levofloxacin ( Levaquin – Ortho-McNeil-Janssen), which has just been approved for generic use by the FDA and has…

Med Lett Drugs Ther. 2011 Jul 11; 53(1368):55-6
A Medical Letter reader has asked us to review the safety of the fluoroquinolone antibiotic levofloxacin ( Levaquin – Ortho-McNeil-Janssen), which has just been approved for generic use by the FDA and has been at the center of some recent lawsuits regarding the adequacy of its safety warnings.
Issue 1356 · January 24, 2011
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin

The FDA has approved ceftaroline fosamil ( Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by…

Med Lett Drugs Ther. 2011 Jan 24; 53(1356):5-6
The FDA has approved ceftaroline fosamil ( Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), and for treatment of community-acquired bacterial pneumonia in adults. It is the first beta-lactam antibiotic approved for treatment of MRSA.
Issue 1344 · August 9, 2010
Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis

The antibiotic aztreonam is now available as an inhalation solution ( Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa .…

Med Lett Drugs Ther. 2010 Aug 9; 52(1344):63-4
The antibiotic aztreonam is now available as an inhalation solution ( Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa . It is the second inhaled antibiotic to be FDA-approved for this indication in CF patients; the aminoglycoside tobramycin (Tobi) was the first. Inhaled antibiotics offer the advantage of high airway concentrations while minimizing systemic side effects.
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 1278 · January 28, 2008
Doripenem (Doribax) - A New Parenteral Carbapenem

Doripenem ( Doribax - Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of…

Med Lett Drugs Ther. 2008 Jan 28; 50(1278):5-7
Doripenem ( Doribax - Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of complicated intra-abdominal and urinary tract infections. Use of doripenem for treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is still under FDA review.
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 1217 · September 12, 2005
Tigecycline (Tygacil)

Tigecycline ( Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.

Med Lett Drugs Ther. 2005 Sep 12; 47(1217):73-4
Tigecycline ( Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 13 · September 1, 2003
Drugs for Pneumonia

The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid…

Treat Guidel Med Lett. 2003 Sep; 1(13):83-8
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Issue 1111 · August 20, 2001
The Choice of Antibacterial Drugs

New drugs for treatment of bacterial infections and new information about older drugs continue to become available. Empirical treatment of some infections is discussed and a table listing the drugs of choice…

Med Lett Drugs Ther. 2001 Aug 20; 43(1111):69-78
New drugs for treatment of bacterial infections and new information about older drugs continue to become available. Empirical treatment of some infections is discussed and a table listing the drugs of choice and alternatives for each pathogen are contained in this article. These recommendations are based on results of susceptibility studies, clinical trials and opinions of Medical Letter consultants. Local resistance patterns should be taken into account.
Issue 1064 · October 22, 1999
The Choice of Antibacterial Drugs

Since The Medical Letter last reviewed the choice of drugs for treatment of bacterial infections, a few new drugs and some new information about older drugs have become available.

Med Lett Drugs Ther. 1999 Oct 22; 41(1064):95-104
Since The Medical Letter last reviewed the choice of drugs for treatment of bacterial infections, a few new drugs and some new information about older drugs have become available.